JP Morgan Chase
ELTX icon

JP Morgan Chase’s Elicio Therapeutics ELTX Stock Holding History

JP Morgan Chase’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5K Buy
+5,372
New +$53.9K ﹤0.01% 6712
2025
Q2 		– Sell
-16
Closed -$99 – 7232
2025
Q1 		$99 Sell
16
-2
-11% -$15 ﹤0.01% 6874
2024
Q4 		$88 Hold
18
– – ﹤0.01% 7027
2024
Q3 		$91 Buy
+18
New +$80 ﹤0.01% 7014
2022
Q2 		– Sell
-14,185
Closed -$300K – 6554
2022
Q1 		$300K Sell
14,185
-335
-2% -$7.56K ﹤0.01% 4972
2021
Q4 		$421K Sell
14,520
-530
-4% -$26.8K ﹤0.01% 4941
2021
Q3 		$1.47M Sell
15,050
-3,662
-20% -$396K ﹤0.01% 4020
2021
Q2 		$2.44M Buy
18,712
+763
+4% +$110K ﹤0.01% 3652
2021
Q1 		$3.24M Buy
+17,949
New +$3.46M ﹤0.01% 3333

Other funds holding ELTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase's ELTX Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 5,372 shares worth $21.5K. The stake represents ﹤0.01% of the portfolio and ranks #6712 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in ELTX as recently as Q1 2025.

JP Morgan Chase first reported a position in ELTX in Q1 2021 and has held it in 9 quarters since. The position peaked at $3.24M in Q1 2021. 46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • JP Morgan Chase held 5,372 shares of Elicio Therapeutics worth $21.5K as of Q2 2026.
  • Elicio Therapeutics was a new JP Morgan Chase position in Q2 2026.
  • Elicio Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6712 holding.
  • JP Morgan Chase first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • JP Morgan Chase's Elicio Therapeutics position peaked at $3.24M in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.